PharmaLundensis AB — Investor Relations & Filings

PharmaLundensis AB is a pharmaceutical research company that develops treatments for diseases with significant unmet needs. The company's primary project is the development of PHAL-501, a drug candidate designed to bind and excrete heavy metals such as mercury, lead, and cadmium from the body. The therapeutic works within the intestine to capture these metals, which are then removed through excretion. This mechanism is intended to prevent the drug from entering the bloodstream, suggesting a favorable safety profile with minimal side effects. PharmaLundensis is investigating this approach for its potential to provide health improvements in several conditions, including Chronic Obstructive Pulmonary Disease (COPD) and illnesses related to heavy metal toxicity.